academy biomed/[P11] Human Apolipoprotein CI (Apo CI)/866,academy biomed,,academy biomed,academybiomed,+,,Array.Array蚂蚁淘厂家直采.

产品名称：academy biomed/[P11] Human Apolipoprotein CI (Apo CI)/866

产品编号：866

市场价：¥0.00

场地：美国(厂家直采)

产品分类：试剂盒>其它试剂盒>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：待定

品牌： academy biomed

公司：academybiomed

公司分类：

商品介绍

Concentration:	1 mg / ml, determined by the Lowry method
Source:	From fresh human plasma that has tested negative for Hepatitis C, HIV-I and HIV-II antibodies as well as Hepatitis surface antigens.
Purification:	After series ultracentrifugations, Very Low Density Lipoprotein (VLDL) is isolated from human plasma. Apo CI is purified from delipidated VLDL, followed by gel-filtration and DEAE-Sepharcyl chromatography.
Purity:	≥ 98% by SDS-PAGE
Buffer:	In 75 mM Sodium Phosphate, 75 m M NaCl, 0.02 % NaN3, 1 mM EDTA, p H 7.4.
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

*The products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

Importance

ApoCI contains 57 amino acid residues and the m.w. is 6.6 kDa (Jackson et al., 1974).

ApoCI has been found to activate LCAT (Liu and Subbaiah 1993). Apo CI is an inhibitor of lipoprotein binding to the LDL receptor, LDL receptor-related protein, and VLDL receptor. Apo CI is also an inhibitor of the plasma cholesteryl ester transfer protein and of fatty acid uptake into tissues (Shachter, 2001). This inhibition role can potentially regulate several lipase enzymes (Poensgen, 1990, Conde-Knape et al., 2002; Berbee et al., 2005.)

Berbee J.F., C.C. van der Hoogt, D. Sundararaman, L.M. Havekes, and P.C. Rensen. “Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.” J. Lipid. Res. 46 (2005) 297-306.

Conde-Knape K., A. Bensadoun, J.H. Sobel. J.S. Cohn, and N.S. Shachter. “Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase” J. Lipid Res. 43 (2002): 2136-2145.

Jackson R.L., J. T. Sparrow, H. N. Baker, J.D. Morrisett, O. D. Taunton, and A. M. Jr. Gotto. “The primary structure of apolipoprotein-serine.” J. Biol. Chem. 249.16 (1974): 5308-13.

Liu, M. and P.V. Subbaiah. “Activation of plasma lysolecithin acyltransferase reaction by apolipoproteins A-I, C-I and E.” Biochim. Biophys. Acta. 1168 (1993): 144-152.

Poensgen, J., “Apolipoprotein C-1 inhibits the hydrolysis by phospholipase A2 of phospholipids in liposomes and cell membranes” Biochim. Biophys. Acta. 1042 (1990): 188-192.

Shachter, Neil S., “Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism” Current Opinion in Lipidology 12(3): 297-304.

Citations

[P11][P12]	2017	Toth, Christopher A.; Kuklenyik, Zsuzsanna; Jones, Jeffrey I.; Parks, Bryan A.; Gardner, Michael S.; Schieltz, David M. et al. (2017): On-column trypsin digestion coupled with LC-MS/MS for quantification of apolipoproteins. In Journal of proteomics 150, pp. 258–267. DOI: 10.1016/j.jprot.2016.09.011.
[P11][P12]	2015	Trenchevska, Olgica; Schaab, Matthew R.; Nelson, Randall W.; Nedelkov, Dobrin (2015): Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. In Methods (San Diego, Calif.) 81, pp. 86–92. DOI: 10.1016/j.ymeth.2015.02.020.
[P11][P12]	2011	Borges, Chad R.; Oran, Paul E.; Buddi, Sai; Jarvis, Jason W.; Schaab, Matthew R.; Rehder, Douglas S. et al. (2011): Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. In Clinical chemistry 57 (5), pp. 719–728. DOI: 10.1373/clinchem.2010.156976.
[P11][P12]	2006	Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743.

品牌介绍

Academy Bio-Medical Company，Inc.专营人类脂蛋白，载脂蛋白和多克隆抗体。以可承受的价格制造和提供高质量的抗体。

自1995年以来，该公司一直以研究试剂为心血管和动脉粥样硬化研究界提供支持。我们自豪地提供致力于脂蛋白，载脂蛋白及其氧化修饰产品领域研究的抗体和试剂。我们的抗体产品得到我们技术服务专家的全面支持。

公司介绍

产品分类

更多...

Proteins Other Products Antibodies

销售排行

更多...